Ipca Laboratories Ltd (IPCALAB) — shareholding pattern, promoter holding, financials and share price
About Ipca Laboratories Ltd (IPCALAB)
Ipca Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as IPCALAB and on the BSE under scrip code 524494. Its ISIN is INE571A01038.
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Ipca Laboratories is a fully integrated Indian pharmaceutical company manufacturing and marketing over 350 formulations and about 80 APIs from 18 Indian manufacturing sites, selling products in more than 100 countries with approvals from major regulators including US FDA, MHRA, ANVISA and TGA and a strong legacy in select APIs such as atenolol and chloroquine.
Recent operating momentum: management reported domestic formulations growth of roughly 12% in the quarter, export formulations growth of circa 17% in Q3 and consolidated nine‑month revenue up about 8.4% to INR7,258 crore; standalone and consolidated EBITDA margins improved materially year‑on‑year, driven by mix shifts toward higher‑margin branded and promotional businesses.
Listed peers in Pharmaceuticals: Abbott India Ltd, Ajanta Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd, Gland Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹1,786.75 a share on 10 Jul 2026, Ipca Laboratories Ltd (IPCALAB) was valued at a price-to-earnings ratio of 38.05x against an industry P/E of 36.41x and a price-to-book of 6.52x on a book value of ₹273.88 per share as of Mar 2025. Solomo computes return on equity of 17.15% and return on capital employed of 19.83% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 38.05x
- Industry P/E
- 36.41x
- P/B
- 6.52x
- EPS (TTM)
- ₹46.96
- Book value / share
- ₹273.88
- ROE
- 17.15%
- ROCE
- 19.83%
- ROA
- 10.13%
- Debt / equity
- 0.2x
- Dividend yield
- 0.11%
- EBITDA margin
- 21.42%
- 52-week range
- ₹1,252.95 – ₹1,812.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Ipca Laboratories Ltd (IPCALAB) reported revenue of ₹9,599 crore, net profit of ₹1,184 crore and earnings per share of ₹44.98. That compares with revenue of ₹8,897 crore and net profit of ₹785 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2,388 crore and net profit ₹307 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 |
| Net profit (₹ cr) | 890 | 479 | 523 | 785 | 1,184 |
| EPS (₹) | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.95% | 8.86% | 7.08% | 16.02% |
| Profit growth | 24.20% | -0.05% | -8.89% | 48.81% |
| Stock price CAGR | 23% | 13% | 34% | 29% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 44.72% of Ipca Laboratories Ltd (IPCALAB) (unchanged from the previous quarter), foreign institutional investors (FII) hold 10.73% and domestic institutional investors (DII) hold 37.37%. Market capitalisation was ₹45,331 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Hdfc Mutual Fund 9.54%, Kotak Mahindra Mutual Fund 6.36%, DSP Mutual Fund 4.64%, Sbi Life Insurance Co. Ltd 3.69%, Nippon India Mutual Fund 2.79%, AXIS MUTUAL FUND 1.94%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 44.72% | - | 10.73% | 37.37% | 55.28% |
| Mar 2026 | 44.72% | - | 10.63% | 37.45% | 55.28% |
| Dec 2025 | 44.72% | - | 10.63% | 37.32% | 55.28% |
| Sep 2025 | 44.72% | - | 10.43% | 36.77% | 55.28% |
| Jun 2025 | 44.72% | - | 10.67% | 36.2% | 55.28% |
| Mar 2025 | 44.72% | - | 10.76% | 36.06% | 55.28% |
| Dec 2024 | 44.72% | - | 11.07% | 35.68% | 55.28% |
| Sep 2024 | 46.3% | - | 10.83% | 34.23% | 53.7% |